SCHEMBL870085

SCHEMBL870085

CC(C)(C)N(C(=O)O)c1ncccc1Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
BLM P54132 1/20 0.36
AGER Q15109 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.35
NAPRT Q6XQN6 1/20 0.35
GRM4 Q14833 1/20 0.35
MYC P01106 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
AR P10275 1/20 0.33
CDK9 P50750 1/20 0.33
DYRK1A Q13627 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
HPGD P15428 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3398126 0.81 NAPRT (0.39) KDM4EALDH1A1MAPTCYP3A4ALOX15
SCHEMBL2302256 0.79 KDM4E (0.42) KDM4EALDH1A1MAPTCYP3A4ALOX15
SCHEMBL1353016 0.78 TRIM24 (0.41) KDM4EALDH1A1MAPTCYP3A4ALOX15
SCHEMBL5582871 0.77 KDM4E (0.36) KDM4EALDH1A1MAPTCYP3A4ALOX15
SCHEMBL15240963 0.76 ERN1 (0.35)
SCHEMBL17700417 0.75 KDM4E (0.38) KDM4EALDH1A1MAPTCYP3A4ALOX15
SCHEMBL15175542 0.73 GRM4 (0.38) KDM4EALDH1A1MAPTCYP3A4TSHR
SCHEMBL20631816 0.72 SSTR4 (0.41) KDM4EALDH1A1NPSR1L3MBTL1POLB
SCHEMBL27193312 0.72 CNR2 (0.32)
SCHEMBL1819971 0.71 POLB (0.55) KDM4EALDH1A1TSHRNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916551-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-12-23 US disclosed
US-20140080817-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-20 US disclosed
US-20120077799-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080817-A1 HETEROCYCLIC COMPOUND AND USE THEREOF GRIN1, GRIN2C, GRIN2A KDM4E 1330/4885ALDH1A1 177/4885MAPT 277/4885
US-20120077799-A1 HETEROCYCLIC COMPOUND AND USE THEREOF GRIN1, GRIN2C, GRIN2A KDM4E 1330/4885ALDH1A1 177/4885MAPT 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.